Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adalimumab vs placebo Adverse events · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Clostridium probiotic vs placebo Clinical remission · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Clostridium probiotic vs placebo Clinical improvement · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Clostridium probiotic vs placebo Maintenance of clinical remission · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Clostridium probiotic vs placebo No of episodes of acute pouchitis · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 0.22 [0.03, 1.6] | 1 study · 17 participants | Very low |
Clostridium probiotic vs placebo Adverse events · Patients with ileal pouch‐anal anastomosis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Metronidazole vs budesonide enema Clinical improvement · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 0.86 [0.42, 1.74] | 1 study · 26 participants | Very low |
Metronidazole vs budesonide enema Maintenance of clinical remission · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Metronidazole vs budesonide enema No episodes acute pouchitis · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of AAD · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections Probiotics for the prevention of pediatric antibiotic‐associated diarrhea (2019) · Cochrane | RR 0.45 [0.36, 0.56] | 33 studies · 6352 participants | Moderate |
Intervention NR Incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections Probiotics for the prevention of pediatric antibiotic‐associated diarrhea (2019) · Cochrane | RR 0.37 [0.3, 0.46] | 20 studies · 4038 participants | Moderate |
Intervention NR Adverse events · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections Probiotics for the prevention of pediatric antibiotic‐associated diarrhea (2019) · Cochrane | no estimate extracted | 24 studies · 4415 participants | Low |
Intervention NR Duration of diarrhea (days) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections Probiotics for the prevention of pediatric antibiotic‐associated diarrhea (2019) · Cochrane | no estimate extracted | 8 studies · 1263 participants | Low |
Intervention NR Microbiome characteristics · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections Probiotics for the prevention of pediatric antibiotic‐associated diarrhea (2019) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
5‐ASA vs no treatment Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.71 [0.46, 1.1] | 110 participants | Low |
5‐ASAs vs placebo Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASAs vs placebo Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.07 [0.6, 1.91] | 4 studies · 466 participants | Low |
5‐ASAs vs placebo Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.06 [0.44, 2.59] | 3 studies · 577 participants | Low |
5‐ASAs vs placebo Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.5 [0.71, 3.19] | 3 studies · 297 participants | Low |
5‐ASAs vs placebo Health related quality of life · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
High dose 5‐ASA vs low dose 5‐ASA Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.65 [0.38, 1.13] | 1 study · 206 participants | Moderate |
High dose 5‐ASA vs low dose 5‐ASA Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.79 [0.6, 1.04] | 1 study · 206 participants | Moderate |
High dose 5‐ASA vs low dose 5‐ASA Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
High dose 5‐ASA vs low dose 5‐ASA Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.04 [0.15, 7.24] | 1 study · 206 participants | Low |
High dose 5‐ASA vs low dose 5‐ASA Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASA vs no treatment Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
High dose 5‐ASA vs low dose 5‐ASA Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.04 [0.15, 7.24] | 1 study · 206 participants | Low |
High dose 5‐ASA vs low dose 5‐ASA Health related quality of life · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASA vs purine antimetabolites Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.9 [0.76, 1.07] | 4 studies · 347 participants | Low |
5‐ASA vs purine antimetabolites Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.29 [0.86, 1.94] | 1 study · 35 participants | Very low |
5‐ASA vs purine antimetabolites Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.09 [0.78, 1.52] | 1 study · 35 participants | Very low |
5‐ASA vs purine antimetabolites Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.11 [0.97, 1.27] | 5 studies · 425 participants | Low |
5‐ASA vs purine antimetabolites Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.3 [0.11, 0.8] | 3 studies · 311 participants | Very low |
5‐ASA vs purine antimetabolites Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.48 [0.28, 0.83] | 5 studies · 425 participants | Low |
5‐ASA vs purine antimetabolites Health related quality of life · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.42 [0.27, 7.46] | 1 study · 35 participants | Very low |
5‐ASAs vs anti TNF‐ɑ Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 4 [1.01, 15.84] | 1 study · 34 participants | Very low |
5‐ASA vs no treatment Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASAs vs anti TNF‐ɑ Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 13.33 [1.98, 89.95] | 1 study · 34 participants | Very low |
5‐ASAs vs anti TNF‐ɑ Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 13.33 [1.98, 89.95] | 1 study · 34 participants | Very low |
5‐ASAs vs anti TNF‐ɑ Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 1.13 [0.75, 1.71] | 1 study · 34 participants | Very low |
5‐ASAs vs anti TNF‐ɑ Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASAs vs anti TNF‐ɑ Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.3 [0.01, 6.84] | 1 study · 34 participants | Very low |
5‐ASAs vs anti TNF‐ɑ Health related quality of life · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.19 [0.07, 0.54] | 1 study · 34 participants | Very low |
Sulphasalazine vs placebo Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.88 [0.56, 1.38] | 2 studies · 298 participants | Low |
Sulphasalazine vs placebo Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulphasalazine vs placebo Radiologic relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulphasalazine vs placebo Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐ASA vs no treatment Adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 5 [0.25, 101.81] | 110 participants | Very low |
Sulphasalazine vs placebo Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Sulphasalazine vs placebo Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane | RR 0.35 [0.01, 8.38] | 1 study · 66 participants | Very low |